Lenalidomide Eg

Lenalidomide, the active ingredient in Lenalidomide Eg, is a immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients. It belongs to the antineoplastic therapeutic class and is administered under medical supervision.

GNH USA supplies Lenalidomide Eg as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing reliable sourcing for hospitals, oncology centres, pharmacies and clinics worldwide. The product is manufactured in the European Union and distributed under strict quality‑assurance protocols.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts in affected adults. - Mantle Cell Lymphoma: induces remission and prolongs disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to easy bruising. - Diarrhea: loose stools that may be mild to moderate. - Constipation: difficulty passing stools. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Severe infections: opportunistic or life‑threatening bacterial, viral or fungal infections. - Second primary malignancies: emergence of new cancers unrelated to original disease. - Teratogenicity: potential to cause fetal malformations if exposure occurs during pregnancy.

Prior to initiating Lenalidomide therapy, several precautions should be observed to ensure patient safety. - Pregnancy: contraindicated (Category X) due to high teratogenic risk; effective contraception required. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: evaluate kidney function and adjust dose if necessary. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Drug interactions: avoid concomitant use with strong CYP3A4 inducers and monitor with anticoagulants. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression. - Pregnancy: co‑administration with teratogenic agents compounds fetal risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase lenalidomide plasma levels; monitor for toxicity. - NSAIDs: combined use may elevate risk of renal impairment and gastrointestinal bleeding.